These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 26340704)

  • 1. Body Composition and Epicardial Fat in Type 2 Diabetes Patients Following Insulin Detemir Versus Insulin Glargine Initiation.
    Elisha B; Azar M; Taleb N; Bernard S; Iacobellis G; Rabasa-Lhoret R
    Horm Metab Res; 2016 Jan; 48(1):42-7. PubMed ID: 26340704
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of basal insulin therapy on vascular endothelial function and adipokine profiles in people with Type 2 diabetes.
    Makino H; Tanaka A; Hosoda H; Koezuka R; Tochiya M; Ohata Y; Tamanaha T; Miyamoto Y; Kangawa K; Kishimoto I
    Diabet Med; 2016 Dec; 33(12):1737-1743. PubMed ID: 27150701
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detemir vs Glargine: Comparison of Inpatient Glycemic Control.
    Capson J; Cade K; Avanesyan A
    J Am Osteopath Assoc; 2019 Feb; 119(2):89-95. PubMed ID: 30688354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COMPARISON OF EFFICACY AND SAFETY OF GLARGINE AND DETEMIR INSULIN IN THE MANAGEMENT OF INPATIENT HYPERGLYCEMIA AND DIABETES.
    Galindo RJ; Davis GM; Fayfman M; Reyes-Umpierrez D; Alfa D; Peng L; Tamler R; Pasquel FJ; Umpierrez GE
    Endocr Pract; 2017 Sep; 23(9):1059-1066. PubMed ID: 28683239
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-acting Insulin Analogs Effect on gh/igf Axis of Children with Type 1 Diabetes: a Randomized, Open-label, Two-period, Cross-over Trial.
    Cherubini V; Pintaudi B; Iannilli A; Pambianchi M; Ferrito L; Nicolucci A
    Exp Clin Endocrinol Diabetes; 2016 May; 124(5):276-82. PubMed ID: 27023008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the dose-response pharmacodynamic profiles of detemir and glargine in severely obese patients with type 2 diabetes: A single-blind, randomised cross-over trial.
    Bilz S; Flückiger M; Meienberg F; Falconnier C; Keller U; Puder JJ
    PLoS One; 2018; 13(8):e0202007. PubMed ID: 30114246
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes.
    Klein O; Lynge J; Endahl L; Damholt B; Nosek L; Heise T
    Diabetes Obes Metab; 2007 May; 9(3):290-9. PubMed ID: 17391154
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Weight gain associated with insulin detemir vs insulin glargine in clinical practice: A retrospective longitudinal cohort study.
    Wadsworth TG; Carr GG; Madaras-Kelly K; Remington R; Bell J
    Am J Health Syst Pharm; 2021 Feb; 78(5):401-407. PubMed ID: 33354715
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Real-world comparative outcomes of US type 2 diabetes patients initiating analog basal insulin therapy.
    Davis KL; Tangirala M; Meyers JL; Wei W
    Curr Med Res Opin; 2013 Sep; 29(9):1083-91. PubMed ID: 23734906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of insulin on body composition in patients with insulin-dependent and non-insulin-dependent diabetes.
    Sinha A; Formica C; Tsalamandris C; Panagiotopoulos S; Hendrich E; DeLuise M; Seeman E; Jerums G
    Diabet Med; 1996 Jan; 13(1):40-6. PubMed ID: 8741811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Similar glucose control with basal-bolus regimen of insulin detemir plus insulin aspart and thrice-daily biphasic insulin aspart 30 in insulin-naive patients with type 2 diabetes: Results of a 50-week randomized clinical trial of stepwise insulin intensification.
    Malek R; Ajili F; Assaad-Khalil SH; Shinde A; Chen JW; Van den Berg E
    Diabetes Metab; 2015 Jun; 41(3):223-30. PubMed ID: 25483023
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of dosing and clinical outcomes in patients undergoing conversion of insulin glargine to insulin detemir.
    Bryant GA; McDanel DL; Horner KE; Farris KB; Newkirk EN
    Pharmacotherapy; 2013 Jan; 33(1):56-62. PubMed ID: 23307546
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The comparison of 24-hour urinary sodium, albumin, and protein excretion in chronic kidney disease patients with type 2 diabetes mellitus using insulin detemir or insulin glargine.
    Afsar B
    Clin Drug Investig; 2013 Oct; 33(10):773-8. PubMed ID: 23943142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How do detemir and glargine compare when added to oral agents in insulin-naïve patients with type 2 diabetes mellitus?
    Marks JB
    Nat Clin Pract Endocrinol Metab; 2008 Sep; 4(9):490-1. PubMed ID: 18594486
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Comparative analysis of insulin glargine vs. insulin detemir: A cost-minimization study applicable to Colombia].
    Fragozo A; Puerta MF; Misas JD
    Biomedica; 2015; 35(2):204-11. PubMed ID: 26535542
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacodynamics and pharmacokinetics of insulin detemir and insulin glargine 300 U/mL in healthy dogs.
    Fink H; Herbert C; Gilor C
    Domest Anim Endocrinol; 2018 Jul; 64():17-30. PubMed ID: 29709796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of the pharmacodynamic profiles of insulin detemir and insulin glargine: a single dose clamp study in people with type 2 diabetes.
    Luzio SD; Dunseath GJ; Atkinson MD; Owens DR
    Diabetes Metab; 2013 Dec; 39(6):537-42. PubMed ID: 24139704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma glucose and hypoglycaemia following exercise in people with Type 1 diabetes: a comparison of three basal insulins.
    Arutchelvam V; Heise T; Dellweg S; Elbroend B; Minns I; Home PD
    Diabet Med; 2009 Oct; 26(10):1027-32. PubMed ID: 19900235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ANALYSIS OF CLINICAL AND LABORATORY PARAMETERS CHILDREN WITH DIABETES MELLIUS TYPE 1 USING DIFFERENT TYPES OF INSULIN PREPARATIONS.
    Ahmadov G
    Georgian Med News; 2023 Mar; (336):63-65. PubMed ID: 37166882
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lower within-subject variability of fasting blood glucose and reduced weight gain with insulin detemir compared to NPH insulin in patients with type 2 diabetes.
    Haak T; Tiengo A; Draeger E; Suntum M; Waldhäusl W
    Diabetes Obes Metab; 2005 Jan; 7(1):56-64. PubMed ID: 15642076
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.